DE69100364T2 - Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung. - Google Patents

Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.

Info

Publication number
DE69100364T2
DE69100364T2 DE91400163T DE69100364T DE69100364T2 DE 69100364 T2 DE69100364 T2 DE 69100364T2 DE 91400163 T DE91400163 T DE 91400163T DE 69100364 T DE69100364 T DE 69100364T DE 69100364 T2 DE69100364 T2 DE 69100364T2
Authority
DE
Germany
Prior art keywords
myristoyl
phenylalanine
diseases
treatment
myristoylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE91400163T
Other languages
English (en)
Other versions
DE69100364D1 (de
Inventor
Michel Vincent
Georges Remond
Yolande Herve
Jean-Albert Boutin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of DE69100364D1 publication Critical patent/DE69100364D1/de
Publication of DE69100364T2 publication Critical patent/DE69100364T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE91400163T 1990-01-25 1991-01-25 Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung. Expired - Fee Related DE69100364T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (2)

Publication Number Publication Date
DE69100364D1 DE69100364D1 (de) 1993-10-21
DE69100364T2 true DE69100364T2 (de) 1994-04-21

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
DE91400163T Expired - Fee Related DE69100364T2 (de) 1990-01-25 1991-01-25 Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.

Country Status (14)

Country Link
US (1) US5164414A (de)
EP (1) EP0443891B1 (de)
JP (1) JPH0717503B2 (de)
AT (1) ATE94387T1 (de)
AU (1) AU633395B2 (de)
CA (1) CA2034861A1 (de)
DE (1) DE69100364T2 (de)
DK (1) DK0443891T3 (de)
ES (1) ES2060310T3 (de)
FR (1) FR2657259A1 (de)
IE (1) IE65573B1 (de)
OA (1) OA09478A (de)
PT (1) PT96571A (de)
ZA (1) ZA91574B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
AU784123B2 (en) * 1999-10-13 2006-02-09 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
WO2003007876A2 (en) * 2001-06-25 2003-01-30 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
RU2665952C2 (ru) 2011-07-22 2018-09-05 Пасилекс Фармасьютикалз Инк. Синтетическая летальность и лечение рака
JP6224072B2 (ja) 2012-03-30 2017-11-01 ジボダン エス エー フレーバープロフィール食用組成物の改良のためのｎ−アシル−アミノ酸誘導体
SG11201405413SA (en) 2012-03-30 2014-10-30 Givaudan Sa N-acyl derivatives of gamma amino - butyric acid and and beta alanine as food flavouring compounds
CA2868058C (en) 2012-03-30 2019-12-17 Givaudan S.A. N-acylated methionine derivatives as food flavouring compounds
KR102125587B1 (ko) 2012-03-30 2020-06-23 지보당 에스아 식품 향미 화합물인 n-아실-아미노산 유도체, 이를 함유하는 분말 조성물
CN104219966B (zh) 2012-03-30 2019-05-28 奇华顿股份有限公司 作为食品加香化合物的n-酰基-氨基酸衍生物
JP6209588B2 (ja) 2012-03-30 2017-10-04 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシルプロリン誘導体
CA2867329C (en) 2012-03-30 2020-03-10 Givaudan S.A. N-acylated 1 - aminocycloalkyl carboxylic acids as food flavouring compounds
CA2890113C (en) * 2012-10-30 2023-01-17 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
EP3057446B1 (de) 2013-10-02 2017-12-06 Givaudan S.A. Organische verbindungen mit geschmacksmodifizierenden eigenschaften
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
US20160227825A1 (en) 2013-10-02 2016-08-11 Givaudan Sa Organic Compounds having Taste-Modifying Properties
WO2015050538A1 (en) * 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
WO2015050536A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. N-acylated 2-aminoisobutyric acid compounds and flavour compositions containing them
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
WO2015048990A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
US10674755B2 (en) 2013-10-02 2020-06-09 Givaudan S.A. Organic Compounds
ES2964607T3 (es) 2015-07-17 2024-04-08 Pacylex Pharmaceuticals Inc Silenciamiento epigenético de NMT2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I

Also Published As

Publication number Publication date
ES2060310T3 (es) 1994-11-16
JPH0717503B2 (ja) 1995-03-01
US5164414A (en) 1992-11-17
FR2657259B1 (de) 1994-08-19
AU6998791A (en) 1991-08-01
CA2034861A1 (fr) 1991-07-26
JPH04210916A (ja) 1992-08-03
IE65573B1 (en) 1995-11-01
DE69100364D1 (de) 1993-10-21
ATE94387T1 (de) 1993-10-15
DK0443891T3 (da) 1993-12-27
AU633395B2 (en) 1993-01-28
EP0443891A1 (de) 1991-08-28
FR2657259A1 (fr) 1991-07-26
IE910242A1 (en) 1991-07-31
OA09478A (fr) 1992-11-15
EP0443891B1 (de) 1993-09-15
PT96571A (pt) 1991-10-15
ZA91574B (en) 1991-11-27

Similar Documents

Publication Publication Date Title
DE69100364T2 (de) Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE29507925U1 (de) Applikator zur Behandlung eines erhöhten Augeninnendruckes mittels Laserstrahlung
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69229944D1 (de) Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
DE69110779T2 (de) Schilddrüsenhormone zur kardialen behandlung.
DE69313261T2 (de) Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
NO913117D0 (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
DE551180T1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69228235D1 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE135232T1 (de) Pharmazeutische zusammensetzungen zur behandlung von b-zell-entartungen
ATE128354T1 (de) Verwendung von 7-oh-1,2-benzopyron zur herstellung eines arzneimittels zur behandlung von malignen tumoren beim menschen.
DE59107405D1 (de) Ein Imidazobenzodiazepin zur Behandlung von Schlafstörungen
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
DE69431320D1 (de) Verwendung von menschlichem Interferon-d zur Herstellung eines Arzneimittels zur Behandlung von Atemwegserkrankungen in Katzen
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen
DE69203098D1 (de) Verwendung eines Polypeptids mit humaner Interleukin-2 Aktivität zur Herstellung pharmazeutischer Zusammensetzungen zur Behandlung von Pneumothoraxen.
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE49965T1 (de) Verwendung von 2-beta-d-ribofuranosylthiazol-4carboxamiden zur herstellung von medikamenten zur behandlung von krebsartigen tumoren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee